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Essentials
• How thrombocytopenia relates to bleeding in 22q11 deletion syndrome (22q11DS) is not clear.
• Bleeding severity, platelet count and volume, and GPIBB were examined in patients with 22q11DS.
• Macrothrombocytopenia and bleeding typified imperfectly overlapping subsets of 22q11DS patients.
• GPIBB hemizygosity does not cause macrothrombocytopenia or bleeding in patients with 22q11DS.
Summary. Background and objectives: Macrothrombocytopenia and bleeding are frequently associated with 22q11 deletion syndrome (22q11DS). GPIBB, which encodes the glycoprotein (GP) Ibb subunit of GPIb-IX-V, is commonly deleted in patients with 22q11DS. Absence of functional GPIb-IX-V causes Bernard-Soulier syndrome, which is a severe bleeding disorder characterized by macrothrombocytopenia. Patients with 22q11DS are often obligate hemizygotes for GPIBB, and those with only a pathogenically disrupted copy of GPIBB present with Bernard-Soulier syndrome. The objective of this study was to determine how GPIBB hemizygosity and sequence variation relate to macrothrombocytopenia and bleeding in patients with 22q11DS who do not have Bernard-Soulier syndrome. Patients/methods: We thoroughly characterized bleeding severity, mean platelet volume, platelet count and GPIBB copy number and sequence in patients with 22q11DS. Results and conclusions: Macrothrombocytopenia and mild bleeding were observed in incompletely overlapping subsets of patients, and GPIBB copy number and sequence variation did not correlate with either macrothrombocytopenia or bleeding in patients with 22q11DS. These findings indicate that GPIBB hemizygosity does not result in either macrothrombocytopenia or bleeding in these patients. Alternative genetic causes of
Introduction
Chromosomal rearrangements that occur early in embryogenesis frequently cause birth defects. Four low-copy repeats (LCRs) located within the q11 region of chromosome 22 enable chromosomal rearrangements to occur at a high frequency [1] , making chromosome 22q11 deletion syndrome (22q11DS) the most common microdeletion syndrome in humans (reviewed in [2] [3] [4] [5] [6] [7] [8] ). The segments of DNA that are commonly deleted in 22q11DS encompass genes that are important for the development of organs that derive from the pharyngeal apparatus, which include the heart, face, thymus, and parathyroid glands (reviewed in [3] ). Consequently, 22q11DS is characterized by cardiac defects, abnormal facial features, thymic hypoplasia, cleft palate, and hypocalcemia, which show variable expressivity [9] [10] [11] [12] [13] [14] [15] . Thrombocytopenia and excessive bleeding have both been reported in patients with 22q11DS; however, the relationship between these conditions is complex and poorly understood. The simplest and best understood relationship, which is also the rarest, occurs in conjunction with Bernard-Soulier syndrome. Bernard-Soulier syndrome is a rare, autosomal recessive, severe bleeding disorder that is characterized by low numbers of large platelets (i.e. macrothrombocytopenia) that are also dysfunctional (reviewed in [16] [17] [18] [19] ). Bernard-Soulier syndrome results from failure of platelets to express a functional form of the glycoprotein (GP) Ib-IX-V complex, which is essential for platelets to adhere to and initiate hemostasis at sites of vessel injury [20] . GPIb-IX-V is composed of four different subunits (GPIba, GPIbb, GPIX, and GPV), of which three (GPIba, GPIbb, and GPIX) are required for surface expression of the complex [21] and one (GPV) is not [22] . Bernard-Soulier syndrome is typically the manifestation of homozygous or compound heterozygous pathogenic variants in the genes encoding GPIba, GPIbb, and GPIX; variants in the gene encoding GPV have thus far not been associated with Bernard-Soulier syndrome [23] . Patients with 22q11DS are at higher than normal risk for the development of Bernard-Soulier syndrome because they are hemizygous for GPIBB, which is the gene that encodes GPIbb [24] . Since the first report of Bernard-Soulier syndrome in association with 22q11DS, in which the absence of GPIBb was confirmed [24] and a pathogenic variant in the GPIBB promoter was subsequently identified [25] , several additional cases attributable to pathogenic nonsense [26] or missense [27] [28] [29] variants in GPIBB have been described. All of these patients had classical phenotypic features of Bernard-Soulier syndrome.
The relationship between macrothrombocytopenia and excessive bleeding in patients with 22q11DS is much more complex and perplexing. Case reports have documented both the absence of any bleeding problems [30] [31] [32] [33] and the occurrence of life-threatening and sometimes fatal hemorrhage [34] [35] [36] [37] in patients with 22q11DS. In most cases, these patients were found to have had large platelets and platelet counts that were either low or at the low end of normal. Several case series have reported that patients with 22q11DS have, on average, larger platelets and lower platelet counts than normal, and either no or mild bleeding symptoms [30, [38] [39] [40] [41] [42] . One case series reported an increased need for blood products following heart surgery among patients with 22q11DS, especially among those with large platelets, relative to patients with other causes of heart defects [43] . In the vast majority of these studies, GPIBB copy number and sequence information were not obtained. Consequently, it remains poorly understood how macrothrombocytopenia relates to excessive bleeding, and how GPIBB copy number and sequence variation relate to either macrothrombocytopenia or excessive bleeding, in the vast majority of patients with 22q11DS.
The present study was designed to clarify the relationship between bleeding severity and macrothrombocytopenia in patients with 22q11DS, and to evaluate the contribution of GPIBB copy number and sequence variation to both of these phenotypes. To accomplish this goal, we thoroughly characterized a small group of patients with 22q11DS with respect to bleeding severity, mean platelet volume (MPV), platelet count, and copy number and sequence information for GPIBB and other genes that encode requisite subunits of the GPIb-IX-V complex and that are associated with Bernard-Soulier syndrome.
Materials and methods

Patients
This study was approved by the Medical College of Wisconsin Institutional Review Board. A total of 27 patients with a confirmed molecular diagnosis of 22q11.2DS who were being treated at the Children's Hospital of Wisconsin gave consent to be enrolled in the study. Complete sets of data were obtained for 15 patients. Subject selection was unbiased relative to bleeding symptoms. Patients enrolled in this study were genetically unrelated subjects. The ISTH Bleeding Assessment Tool (ISTH-BAT) was applied to enrolled patients to determine the severity of bleeding symptoms [44] . In children, scores of 0-2 prepuberty, <4 postpuberty in males and <6 postpuberty in females define normal levels of bleeding severity [45] . Demographic information, diagnostic test results, platelet counts and MPVs were extracted from medical records. Platelet function testing, GPIb-IX-V expression levels and gene copy number and sequencing results were obtained by the use of blood (5 mL) drawn into a 3.2% sodium citrate tube (BD Biosciences, San Jose, CA, USA). Control gene copy number results were obtained by the use of blood drawn from healthy adult subjects who gave consent to be enrolled in the study.
Flow cytometry
Platelet surface expression levels of the human GPIb-IX-V complex were determined with the GPIba-specific mAb AP1, and levels of expression of the human GPIIb-IIIa complex were determined with the complex-specific mAb AP2. Both antibodies were purchased from the BloodCenter of Wisconsin Hybridoma Core (Milwaukee, WI, USA ).
Gene copy number and sequencing assays
Genomic DNA was prepared with the Gentra Puregene Blood Core Kit B (Qiagen, Hilden, Germany) from buffy coats that were isolated from whole blood. For gene copy number results, real-time quantitative PCR was performed with kits purchased from Life Technologies (Carlsbad, CA, USA) with proprietary primers and probes for the target genes GP1BA, GP9, GP1BB, DGCR6L, MED15, and SEPRIND1, or for RnaseP as a reference. Extracted DNA, primers and probes were combined with TaqMan polymerase (Life Technologies) and run on an ABI 7500 real-time PCR system (Applied Biosystems, Foster City, CA, USA) under conditions that encompassed denaturation at 95°C for 10 min, followed by 40 amplification cycles that involved denaturation at 95°C for 15 s and annealing/extension at 60°C for 1 min. Final copy number analysis was performed with COPY CALLER Version 2.0 (Applied Biosystems), and with possession of two copies of the target genes GP1BB, GP1BA and GP9 in healthy adult controls, and possession of two copies of the reference gene RnaseP in both 22q11.2DS patients and healthy adult controls, as calibrators.
Genomic DNA was amplified, in order to be sequenced, in 10% dimethylsulfoxide (Sigma-Aldrich, Saint Louis, MO, USA) on a T100 thermal cycler (BioRad, Hercules, CA, USA) with a HotStarTaq DNA Polymerase Kit (Qiagen), 10 mol L À1 dNTPs (Life Technologies), and primers that were designed by and purchased from Integrated DNA Technologies (Coralville, IA, USA). The primers used for amplification are shown in Table S1 . The conditions used for amplification of GP1BB and GP9 involved an initial denaturation step at 95°C for 15 min, 35 amplification cycles that involved denaturation at 94°C for 45 s, annealing at 60°C for 1 min, and extension at 72°C for 1 min, and a final extension step of 10 min at 72°C. The conditions used for amplification of GP1BA involved an initial denaturation step at 95°C for 15 min, 45 amplification cycles that involved denaturation at 94°C for 45 s, annealing at 55°C for 1 min, and extension at 72°C for 3 min, and a final extension step at 72°C for 10 min. Amplified DNA was purified with Exo-SAP IT (Applied Biosystems) and sequenced with a BigDye Terminator kit (Thermo Fisher). Primers used for sequencing were designed and purchased from Integrated DNA Technologies, and are shown in Table S1 . Sequencing reactions were performed on a BioRad T100 thermal cycler with one sequencing primer in each reaction and conditions that involved 25 cycles of denaturation at 96°C for 30 s, annealing at 50°C for 15 s, and extension at 60°C for 4 min. Sequencing reactions were cleaned up on Centri-Sep spin columns (Princeton Separations, Freehold, NJ, USA), lyophilized with a Savant DNA120 SpeedVac Concentrator (Thermo Fisher), and analyzed on a 3130xl Genetic Analyzer (Applied Biosystems). Sequences were analyzed for single-nucleotide polymorphisms (SNPs) with SNAPGENE 3.3.3 (GSL Biotech, Chicago, IL, USA) and reference genomic DNA sequences from the NCBI RefSeq database. Non-consensus SNPs in GP1BB, GP1BA and GP9 that were identified in our patients were verified with the NCBI SNP database.
Variable number of tandem repeats (VNTR) analysis
GP1BA has a variable number of tandem repeats (VNTR), each of which encodes a 13 amino acid segment, in the region that encodes the macroglycopeptide stalk of GPIBa [46] . Humans possess four GPIBA VNTR variants with four repeats (haplotype A), three repeats (haplotype B), two repeats (haplotype C), and one repeat (haplotype D) [46, 47] . For patients who were homozygous for the GPIBA VNTR variant, haplotypes were assigned on the basis of GPIBA sequence information. For patients who were heterozygous for the GPIBA VNTR variant, the GPIBA VNTR was amplified by PCR, and haplotypes were assigned on the basis of the pattern of migration of PCR products in an agarose gel. Genomic DNA from heterozygous patients was amplified with the HotStarTaq DNA Polymerase Kit, 10 mol L À1 dNTPs, and primers specific to the VNTR region that were designed by and purchased from Integrated DNA Technologies (Table S1 ). Amplification involved an initial denaturation step at 95°C for 15 min, 30 amplification cycles that involved denaturation at 94°C for 45 s, annealing at 60°C for 1 min, and extension at 72°C for 3 min, and a final extension step at 72°C for 10 min. Amplified PCR products were electrophoresed on a prepared 4% agarose gel (Fisher Scientific, Hampton, NH, USA), stained with ethidium bromide, and imaged with an AlphaImager HP system (Protein Simple, San Jose, CA, USA).
Statistical analysis
Students' t-test was performed with GRAPHPAD PRISM 6 (GraphPad, La Jolla, CA, USA) to determine the statistical significance of differences in the extents of platelet count, MPV and platelet aggregation between patients with high and low ISTH-BAT scores.
Results
Patient characteristics
The ages of the patients ranged from 3 years to 17 years, with a median of 9 years. Half of the patients (8/15, 53.3%) were female. All patients had a confirmed molecular diagnosis of 22q11.2DS, which was based on the results of a fluorescence in situ hybridization test for the majority (9/15, 60%), and the results of a chromosomal microarray test for the remainder of the patients.
Self-reported ISTH-BAT scores
The patients enrolled in our study reported ISTH-BAT scores ranging from 0 to 9, with a median score of 3 ( Table 1 ). The scores of half of the patients (7/15, 46.6%) fell within the normal range. The remainder of the patients (8/15, 53.3%) reported scores reflective of higher than normal levels of bleeding severity. Cutaneous bleeding was the symptom most commonly associated with higher than normal ISTH-BAT scores, with 40% (6/15) of patients (patients 6, 12, 13, 18, 24, and 27) reporting unexplained and/ or frequent bruising, all of whom had higher than normal ISTH-BAT scores. Epistaxis was the next most common symptom, with 25% (4/15) of patients (patients 1, 6, 12, and 25) reporting spontaneous and frequent nosebleeds, three of whom had higher than normal ISTH-BAT scores. Excessive bleeding from the mouth was reported by two patients (patients 10 and 27), one of whom had a higher than normal ISTH-BAT score. Prolonged bleeding from minor wounds (patients 13 and 27) and gastrointestinal bleeding (patients 22 and 25) were each reported by two patients, all four of whom had higher than normal ISTH-BAT scores. The patient with the highest ISTH-BAT score (patient 27) also reported excessive postsurgical bleeding following cardiac surgery with cardiopulmonary bypass. On the basis of these findings, we conclude that the severity of bleeding symptoms was higher than normal in 53% of our cohort of patients with 22q11.2DS. GP1BA VNTR polymorphism haplotypes: B = 3 repeats, C = 2 repeats, D = 1 repeat. NCBI dbSNP ID, Function Class: *rs1059196, 3 0 -untranslated region (UTR); †rs753215807, synonymous codon; ‡new polymorphism, synonymous codon; §rs199616811, 3 0 -UTR; ¶rs762865345, synonymous codon; **rs145319139, upstream variant 2KB; † †rs6069, synonymous codon; ‡ ‡rs6065, missense (T161M).
Gene copy number analysis
We found that, regardless of their ISTH-BAT scores, all of the patients enrolled in our study had two copies of GP1BA and GP9 and one copy of GPIBB (Fig. 1) . With the exception of one patient who had two copies of SER-PIND1, all patients had one copy each of DGCR6L, MED15, and SERPIND1, indicating that their deletion encompassed LCRA-D of chromosome 22 (Fig. 1) . These results signify no relationship between ISTH-BAT scores and either GPIBB copy number or the extent of the deletion within chromosome 22 in patients with 22q11.2DS.
Sequencing of GP1BB, GP1BA, and GP9
Our results revealed seven single-nucleotide variants (SNVs) and one insertion in the genes encoding GP1bb, GP1ba and GPIX in our patients (Table 1) . These included one SNV in GPIBB, two SNVs in GP9, and four SNPs and one insertion in GPIBA. With one exception, all of the sequence variants that we identified have been previously reported ( Table 1 ). The one exception was a synonymous G>A substitution at position 336 within GPIBA. Also with one exception, none of the sequence variants that we identified affected the amino acid sequence of the protein that it encodes. The one exception was a missense C>T substitution at position 482 of GPIBA, which results in substitution of threonine with methionine at position 145 of the mature GPIBa polypeptide and defines the human platelet antigen (HPA)-2b polymorphism (reviewed in [49] ). HPA-2b has been previously associated with thrombocytopenia in genome-wide association studies [50, 51] . Interestingly, the two patients enrolled in our study who possessed this variant also had the lowest platelet counts (117 9 10 3 platelets lL -1 and 120 9 10 3 platelets lL -1
); however, both of these patients reported ISTH-BAT scores of 0. None of the sequence variants that we identified was more prevalent among patients with higher than normal ISTH-BAT scores than among those with normal scores. These results indicate that variants in GPIBB, GPIBA or GP9 are not associated with ISTH-BAT scores in patients with 22q11.2DS.
GPIBA VNTR polymorphisms
The majority of the patients enrolled in our study ( The banding pattern is as depicted at ghr.nlm.nih.gov/chromosome/22. The locations of low-copy repeat (LCR)A, LCRB and LCRD are as described in [48] . The locations of P14KA as a reference point for LCRC and of GPIBB, DGCR6L, MED15 and SERPIND1 are as depicted at www.genecards.org. (B) Reference (RnaseP) and target (GP1BA, GP9, GP1BB, DGCR6L, MED15, and SERPIND1) genes were amplified from genomic DNA extracted from pediatric patients diagnosed with 22q11.2DS. Copy numbers were calculated for each patient, and compared with genomic DNA extracted from a healthy adult (Pos) as a two-copy control calibrator for each target gene. Note that, with the exception of patient 23, who had two copies of SERPIND1, all of the 22q11.2DS patients included in this study had one copy each of GPIBB, DGCR6L, MED15, and SERPIND1, and two copies each of GPIBA and GP9.
VNTR polymorphism (Table 1 ). Of the three remaining patients, two were heterozygous for the CD haplotype and one was heterozygous for the BC haplotype. The finding of either homozygosity or heterozygosity for the C haplotype of the GPIBA VNTR polymorphism in all of our patients is compatible with the previous report that the C haplotype is the most frequent phenotype observed in humans [52] . None of the GPIBA VNTR haplotypes was associated with ISTH-BAT scores in patients with 22q11.2DS.
Platelet number, size, and function
As shown in Table 2 , MPVs were within or above the normal range and platelet counts were within or below the normal range for all 22q11DS patients. Platelet responses to agonist stimulation fell within normal reference ranges for all agonists except collagen and ristocetin. Only one patient in each group showed slightly lower than normal responses to ristocetin; aggregation responses to all other agonists were normal or slightly higher than normal. GPIb-IX-V expression levels ranged from 50% to slightly more than 100% that of the platelet-specific integrin GPIIb for all patients. Median MPVs, platelet counts, levels of GPIb-IX-V expression and agonist-induced platelet aggregation responses did not correlate with ISTH BAT scores. Collectively, the results shown in Table 2 indicate that, in patients with 22q11.2DS, ISTH-BAT scores do not correlate with larger platelets, lower platelet counts, lower levels of GPIb-IX-V expression on platelet surfaces, or platelets that are less responsive to agonist stimulation.
Discussion
This study enabled clarification of the relationship between macrothrombocytopenia and bleeding in patients with 22q11DS by thoroughly characterizing bleeding severity, platelet size and count, and GPIBB genetics in a small group of patients. As summarized in Fig. 2 , we found that the patients included in our study were all hemizygous for GPIBB, and none had a deleterious variant in their sole copy of GPIBB. Approximately 50% of the patients reported higher than normal ISTH-BAT scores, and 25% had MPVs and platelet counts characteristic of macrothrombocytopenia. One patient had thrombocytopenia but not large platelets, and one patient had large platelets but not thrombocytopenia. In patients who had macrothrombocytopenia in association with 22q11DS, bleeding was generally less severe, platelet counts were generally not as low and platelet volumes did not range as high as in previously described patients who had macrothrombocytopenia in association with Bernard-Soulier syndrome that was caused either by homozygous or compound heterozygous pathogenic variants in GPIBB (Table S2) or by hemizygosity for a mutated copy of GPIBB (Table S3 ). The four patients with, and the 11 patients without, macrothrombocytopenia were equally distributed among patients with normal and higher than normal ISTH-BAT scores. These findings reveal that mild macrothrombocytopenia and a mild bleeding diathesis are characteristic of incompletely overlapping subsets of patients, and that neither GPIBB copy number nor GPIBB sequence variation accounts for either macrothrombocytopenia or excessive bleeding in patients with 22q11DS. Only 25% of the patients with 22q11DS in our study had both large platelets and low platelet counts, suggesting that macrothrombocytopenia may not be as representative a feature of the wide spectrum of 22q11DS as has been previously supposed [32, 36, 39, 41, 54, 55] . This supposition is based, in part, on case reports, all of which described patients with large platelets (when platelet size was reported) and platelet counts that dropped below normal on at least one occasion (Table S4 ). Case series of 22q11DS patients have perpetuated the perception that macrothrombocytopenia is characteristic of 22q11DS by reporting that groups of patients with 22q11DS have, on average, higher MPVs and lower platelet counts than control populations (Table S5) . However, the incidence of macrothrombocytopenia was not reported in most studies and, when it was reported, was < 50% [39, 54] . Furthermore, average MPVs and platelet counts may be susceptible to skewing by a small number of patients with high MPVs and/or low platelet counts. The finding that the existence in our study population of only five patients with MPVs of >10 fL brought the mean MPV for all 15 patients up to 10.2 fL, which is comparable to the mean MPVs reported for patients with 22q11DS in other case series, exemplifies the latter problem. On the basis of these findings, we propose that consideration of 22q11.2DS in association with congenital heart disease should not be limited to infants with increased MPV and mild thrombocytopenia [56] , but should be extended to infants without platelet abnormalities as well. Our findings also challenge the prevailing view that GPIBB hemizygosity is the cause of macrothrombocytopenia and a bleeding tendency in patients with 22q11DS [32, [39] [40] [41] 57] . This view is not based on proof of a causal relationship, but is instead founded on the overlap of features observed in 22q11DS with the phenotype observed in individuals with Bernard-Soulier syndrome attributable to hemizygosity or homozygosity for pathogenic variants of GPIBB (Tables S2 and S3) . By determining GPIBB copy number and sequence, platelet size and volume, and bleeding severity in individual patients with 22q11DS, we demonstrate definitively that GPIBB hemizygosity alone is not correlated with either macrothrombocytopenia or a bleeding tendency as measured by the use of ISTH-BAT scores in these patients. Instead, GPIBB hemizygosity shows incomplete penetrance with respect to these traits, which reflects the influence of other genetic loci or environmental factors on macrothrombocytopenia and bleeding in patients with 22q11DS. Other genetic causes of these phenotypes include variations in genes other than GPIBB that are located within the deleted region. One such gene is SEPT5, which resides 250 nucleotides 5 0 of GPIBB and is important for granule exocytosis in platelets and neurons [58] [59] [60] [61] . Homozygous deletion of both GPIBB and SEPT5 was associated with macrothombocytopenia and severe bleeding in a young boy [62] ; however, independent contributions of GPIBB versus SEPT5 deficiency to these phenotypes were not ascertained in this patient. Variants in genes located outside of the deleted region may also cause macrothrombocytopenia and bleeding. Meta-analysis of genome-wide association studies recently identified 68 independent loci associated with MPV and/or platelet count in humans [51] , among which only one (ARVCF) is located within the commonly deleted region in 22q11DS. Whether variants in any of the loci located outside the deleted region cause macrothrombocytopenia and bleeding in patients with 22q11DS remains to be determined. In addition, environmental factors, including surgery or trauma, autoimmune-mediated or alloimmune-mediated platelet destruction, infection-induced or drug-induced bone marrow suppression, or bone marrow failure (reviewed in [63] ), could also cause thrombocytopenia and bleeding in patients with 22q11DS.
On the basis of our understanding of the complex relationship between GPIBB, macrothrombocytopenia and bleeding in patients with 22q11DS, we have developed a decision tree to guide the management of bleeding problems in these patients (Fig. 3) . The tree uses MPV and platelet count data, obtained from a complete blood count, to diagnose (macro)thrombocytopenia and, if it is present, its likely cause. MPVs of >10 fL and platelet counts of <150 000 lL À1 would justify sequencing of GPIBB to molecularly assess for Bernard-Soulier syndrome; if no pathogenic variant of GPIBB is identified, another genetic cause of congenital macrothrombocytopenia should be considered. The degree of thrombocytopenia is the biggest predictor for the risk of bleeding in patients with 22q11DS [30, 32, 34] ; therefore, the types of bleeding expected in patients with 22q11DS would depend between GPIBB hemizygosity and sequence variation, macrothrombocytopenia and bleeding tendency in patients with 22q11 deletion syndrome (22q11DS). All of the patients included in our study were hemizygous for GPIBB, and the sequences of their remaining copies of GPIBB were all normal. Approximately 50% (8/15) of the patients reported higher than normal ISTH Bleeding Assessment Tool (ISTH-BAT) scores of ≥ 3, and an equivalent percentage (7/15) reported ISTH-BAT scores within the normal range of 0-2. Approximately 25% (4/15) of the patients had high mean platelet volumes (MPVs) (> 10 fL) and low platelet counts (< 150 000 lL À1 ), which is characteristic of macrothrombocytopenia. One patient had a high MPV but a normal platelet count, and another patient had a low platelet count but a normal MPV. The four patients with, and the 11 patients without, macrothrombocytopenia were equally distributed among patients with normal and higher than normal ISTH-BAT scores. These findings reveal that mild macrothrombocytopenia and a mild bleeding diathesis are characteristic of incompletely overlapping subsets of patients, and that neither GPIBB copy number nor GPIBB sequence variation accounts for either macrothrombocytopenia or excessive bleeding in patients with 22q11DS. GPIBB, gene encoding glycoprotein Ibb.
on the patient's platelet count. Patients with platelet counts of > 50 000 lL À1 might show mild to moderate bleeding symptoms, whereas those with platelet counts of < 50 000 lL À1 might show severe bleeding. Management of severe bleeding should be dictated by the cause of the low platelet count, and should be compatible with published guidelines [64] [65] [66] [67] . Our findings have potential relevance to the finding of rare variants of GPIBB that, in heterozygous form, are associated with macrothrombocytopenia [68] . Individuals who are heterozygous for such variants are similar to patients with 22q11DS in that they possess only one copy of a normal GPIBB allele but different in that they also possess a variant GPIBB allele. Whether macrothrombocytopenia in these individuals is attributable to autosomal dominance of the variant GPIBB allele or to variants in other genetic loci depends on how each GPIBB variant affects the expression and function of GPIb-IX-V.
Variants that encode a form of GPIBb that either does not allow trafficking of GPIb-IX-V to the platelet surface or allows trafficking to the surface but causes GPIb-IX-V to be dysfunctional would be autosomal dominant and cause macrothrombocytopenia. In contrast, variants that abrogate expression of GPIBb would behave like missing alleles, and macrothrombocytopenia that occurs in individuals heterozygous for such alleles would probably be caused by variants in other genetic loci, as they are in patients with 22q11DS. Evaluation of platelet count and size in family members who are homozygous for the wild-type GPIBB allele should help to show whether the GPIBB variant or another genetic variant is responsible for macrothrombocytopenia in individuals who are heterozygous for a given variant GPIBB allele. An interesting case in point is a previously described family [69] in which members who were homozygous for a variant allele of GP9 (N45S) had Bernard-Soulier syndrome, whereas those who were either Platelet count < 50 000/µL Platelet count < 150 000/µL? Fig. 3 . Implications of the findings for the management of patients with 22q11 deletion syndrome. Mean platelet volume (MPV) and platelet count data can be acquired by performing a complete blood count, and used to diagnose thrombocytopenia and, if it is present, its likely cause. MPVs of > 10 fL and platelet counts of < 150 000 lL À1 would support a diagnosis of macrothrombocytopenia; subsequent identification of pathogenic variants in GPIBB would support a diagnosis of Bernard-Soulier syndrome, whereas their absence would support a diagnosis of congenital macrothrombocytopenia caused by another gene defect. MPVs of > 10 fL and platelet counts of ≥ 150 000 lL À1 would justify diagnosis of a giant platelet disorder. MPVs of ≤ 10 fL and platelet counts of < 150 000 lL À1 would support a diagnosis of thrombocytopenia, and MPVs of ≤ 10 fL and platelet counts of ≥ 150 000 lL À1 would be indicative of normal platelet parameters. The dashed line divides patients on the basis of whether platelet counts are above or below 50 000 lL À1 , which may determine the type of bleeding that might be expected. Mild to moderate bleeding symptoms would be expected in patients with platelet counts above 50 000 lL
À1
, whereas those with platelet counts below 50 000 lL À1 might show severe bleeding. Different factors could cause platelet counts to drop below 50 000 lL À1 , including genetic causes (Bernard-Soulier syndrome) or environmental factors (surgery or exposure to a mechanical device, bone marrow suppression or failure, or platelet clearance by alloantibodies or autoantibodies. Strategies for management of severe bleeding would be determined by the suspected cause of the low platelet count. GPIBB, gene encoding glycoprotein Ibb; ITP, immune thrombocytopenia; NAIT, neonatal alloimmune thrombocytopenia.
heterozygous for the variant allele or homozygous for the wild-type allele generally had large platelets and, in some cases, also had low platelet counts (Fig. S1 ). It is likely that a variant in a genetic locus other than GP9 is responsible for the macrothrombocytopenia associated with heterozygosity for the variant GP9 allele or homozygosity for the wild-type allele in this family. The extent to which variants of GPIBB (Table S6) or GPIBA [70] , in heterozygous form, are associated with macrothrombocytopenia remain to be determined. The limitations of our study are that bleeding severity was assessed with only one bleeding assessment tool, that the study included only a small number of patients, and that the causes of large platelets and/or low platelet counts were not determined for the subset of patients who showed these platelet defects. Future studies should be performed to determine whether the findings are reproducible with other bleeding assessment tools [71, 72] , and whether they can be generalized to a larger, but equally well-characterized, group of patients with 22q11DS. The genetic basis of macrothrombocytopenia in patients with 22q11DS, when it occurs, remains to be conclusively determined. With respect to the latter, patients with 22q11DS may represent a unique and valuable resource for determining how genes other than GPIBB that reside in the deleted region contribute to the formation of platelets of appropriate size, number, and function. Addendum N. M. J. Zwifelhofer acquired data, analyzed and interpreted data, and contributed to critical writing. R. S. Bercovitz contributed to the concept and design, acquired and interpreted data, and revised the intellectual content. A. Moroi acquired data, analyzed and interpreted data, and revised the manuscript. S. LaRose analyzed and interpreted data. L. A. Weik contributed to the concept and design, and acquired data. P. J. Newman contributed to the concept and design, and revised the intellectual content. D. K. Newman contributed to the concept and design, analyzed and interpreted data, and wrote and revised the manuscript.
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